Pulmonary Arterial Hypertension
FREEDOM-EV was an international, multicenter, randomized, double-blind, placebo-controlled trial (N=690) that randomized patients to 3 daily doses of Orenitram or placebo.
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
There were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.
Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.
Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.
Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.
Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.
Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.
There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.
Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.
There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.
Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus comorbid with pulmonary arterial hypertension should be considered separate diseases.
The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.
The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.
Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.
The American Heart Association scientific statement offers recommendations on right-sided heart failure regarding physical examination, serum markers, and imaging.
Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.
Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.
Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.
The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.
Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.
In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.
A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.
Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.
Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.
N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.
A 32-year-old woman presents to the emergency department with complaints of dyspnea on exertion and near syncopal episodes.
Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.
The Cardiology Advisor Articles
- Class 1 Device Recall: Endologix AFX Device Recalled Due to Type III Endoleaks
- Harvard: Fraudulent Data Found in Publications of Heart Researcher
- Traumatic Life Events May Increase Risk for Atrial Fibrillation in Older Women
- No Differences Between Bivalirudin, UFH Post-PCI After Ticagrelor Pretreatment
- Rivaroxaban Approved to Reduce Risk of Major Cardiovascular Events in CAD, PAD
- Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy
- Long-Term Exposure to Elevated BP Associated With AS and AR
- Risk Factors for Atherosclerotic Cardiovascular Disease in the South Asian Population
- Takotsubo Syndrome Associated With Substantial Morbidity, Mortality
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Metformin May Improve Vascular Health in Adolescents With Type 1 Diabetes
- Improved Cardiovascular Event Reporting Needed in Leukemia Clinical Trials
- Psoriasis Associated With Clinical Signs of Accelerated Atherosclerosis
- Can Dermatoscope Magnets Be Used With CV Implanted Electronic Devices?
- The Striking Effects of Diversity in Health Care: Improving Patient Outcomes